Boy Dosed with Pfizer DMD Gene Therapy Dies a Year after Phase II Trial
Pfizer has paused enrollment in a Phase III trial assessing its Duchenne muscular dystrophy (DMD) gene therapy candidate fordadistrogene movaparvovec after acknowledging the sudden death of a young boy who received the treatment last year.